AbbVie’s last stand: How an Icelandic billionaire’s biosimilar has one final shot to dethrone Humira
When AbbVie CEO Richard Gonzalez sat before the House Committee on Oversight last week, calmly fending off questions about his mega-blockbuster Humira and its fortress of patents, the fate of any competition entering the US market before 2023 seemed all but sealed.
But what none of the representatives nor their 57-page report mentioned is that there is still one more biosimilar developer that has a shot at winning FDA approval for its version of Humira in September, and has yet to settle in court with AbbVie.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,700+ biopharma pros reading Endpoints daily — and it's free.